3.07
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché GDRX Giù?
Forum
Previsione
Precedente Chiudi:
$3.17
Aprire:
$3.17
Volume 24 ore:
711.39K
Relative Volume:
0.51
Capitalizzazione di mercato:
$1.04B
Reddito:
$787.89M
Utile/perdita netta:
$20.56M
Rapporto P/E:
52.48
EPS:
0.0585
Flusso di cassa netto:
$96.54M
1 W Prestazione:
+3.72%
1M Prestazione:
+6.60%
6M Prestazione:
+35.24%
1 anno Prestazione:
-35.91%
Goodrx Holdings Inc Stock (GDRX) Company Profile
Nome
Goodrx Holdings Inc
Settore
Industria
Telefono
(855) 268-2822
Indirizzo
2701 OLYMPIC BOULEVARD, SANTA MONICA
Compare GDRX vs VEEV, BTSG, HQY, TEM, TXG
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
|
GDRX
Goodrx Holdings Inc
|
3.07 | 1.03B | 787.89M | 20.56M | 96.54M | 0.0585 |
|
VEEV
Veeva Systems Inc
|
203.77 | 31.59B | 3.32B | 941.65M | 1.64B | 5.6161 |
|
BTSG
Brightspring Health Services Inc
|
59.74 | 14.13B | 13.65B | 169.86M | 412.12M | 1.0758 |
|
HQY
Healthequity Inc
|
100.61 | 8.28B | 1.34B | 230.70M | 440.96M | 2.6695 |
|
TEM
Tempus Ai Inc
|
43.87 | 7.73B | 1.36B | -302.91M | -219.93M | -1.7182 |
|
TXG
10 X Genomics Inc
|
47.27 | 5.83B | 638.78M | -22.66M | 122.18M | -0.1744 |
Goodrx Holdings Inc Stock (GDRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-27 | Downgrade | JP Morgan | Overweight → Neutral |
| 2026-01-22 | Downgrade | Jefferies | Buy → Hold |
| 2025-12-09 | Iniziato | Barclays | Underweight |
| 2025-08-11 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2024-12-04 | Iniziato | Mizuho | Neutral |
| 2024-08-09 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2024-05-23 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-05-16 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2024-04-10 | Aggiornamento | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2024-03-25 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2024-03-01 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2024-02-26 | Iniziato | Leerink Partners | Outperform |
| 2024-01-02 | Downgrade | BofA Securities | Buy → Underperform |
| 2023-08-10 | Aggiornamento | DA Davidson | Neutral → Buy |
| 2023-07-31 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2022-12-01 | Iniziato | Citigroup | Buy |
| 2022-11-04 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2022-09-16 | Iniziato | KeyBanc Capital Markets | Sector Weight |
| 2022-09-07 | Iniziato | Truist | Hold |
| 2022-08-12 | Iniziato | DA Davidson | Neutral |
| 2022-06-10 | Downgrade | Goldman | Buy → Neutral |
| 2022-06-06 | Ripresa | BofA Securities | Buy |
| 2022-06-01 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2022-05-10 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-05-10 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-05-10 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2022-05-10 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2022-04-11 | Iniziato | Wells Fargo | Equal Weight |
| 2022-04-07 | Iniziato | Guggenheim | Buy |
| 2022-04-01 | Ripresa | Credit Suisse | Neutral |
| 2022-03-15 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2022-03-01 | Reiterato | Barclays | Overweight |
| 2022-03-01 | Reiterato | BofA Securities | Neutral |
| 2022-03-01 | Downgrade | Cowen | Outperform → Market Perform |
| 2022-03-01 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2022-03-01 | Reiterato | Evercore ISI | Outperform |
| 2022-03-01 | Reiterato | Goldman | Buy |
| 2022-03-01 | Reiterato | JP Morgan | Underweight |
| 2022-03-01 | Reiterato | RBC Capital Mkts | Outperform |
| 2022-03-01 | Reiterato | SVB Leerink | Outperform |
| 2022-01-07 | Iniziato | Goldman | Buy |
| 2021-12-21 | Iniziato | Stephens | Overweight |
| 2021-12-02 | Iniziato | Jefferies | Buy |
| 2021-08-31 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2021-08-13 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2021-05-28 | Iniziato | Robert W. Baird | Neutral |
| 2021-04-06 | Ripresa | Evercore ISI | Outperform |
| 2021-01-25 | Iniziato | Guggenheim | Buy |
| 2020-11-19 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-11-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-10-19 | Iniziato | Barclays | Equal Weight |
| 2020-10-19 | Iniziato | BofA Securities | Neutral |
| 2020-10-19 | Iniziato | Citigroup | Buy |
| 2020-10-19 | Iniziato | Cowen | Outperform |
| 2020-10-19 | Iniziato | Credit Suisse | Outperform |
| 2020-10-19 | Iniziato | Deutsche Bank | Hold |
| 2020-10-19 | Iniziato | Goldman | Neutral |
| 2020-10-19 | Iniziato | JP Morgan | Neutral |
| 2020-10-19 | Iniziato | Morgan Stanley | Overweight |
| 2020-10-19 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2020-10-19 | Iniziato | SVB Leerink | Outperform |
| 2020-10-19 | Iniziato | UBS | Buy |
Mostra tutto
Goodrx Holdings Inc Borsa (GDRX) Ultime notizie
GoodRx Holdings Inc (GDRX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
GoodRx Holdings Inc (GDRX) Valuation: PE, PB & Fair Value Analysis - TradingKey
GDRX|GoodRx Holdings Inc|Price:3.065|Chg%:+0.105 - TradingKey
GoodRx Holdings Inc (GDRX) Income Statement - TradingKey
GoodRx Holdings Inc (GDRX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
GoodRx Holdings Inc (GDRX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
GoodRx Holdings Inc (GDRX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
GoodRx Holdings Inc (GDRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
GoodRx Holdings Inc (GDRX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
GoodRx Holdings Inc (GDRX) Institutional Confidence - TradingKey
Teladoc, GoodRx shares fall on OpenAI health feature launch By Investing.com - Investing.com Australia
GoodRx (GDRX) Receives Positive Analyst Outlook with $4 Price Ta - GuruFocus
GoodRx (GDRX): Buy, Sell, or Hold Post Q1 Earnings? - Yahoo Finance
GoodRx Holdings, Inc. (GDRX) Stock Analysis: Navigating Healthcare with a 1.30% Upside Potential - DirectorsTalk Interviews
GoodRx Holdings (GDRX) Posts Modest Gain as Stock Hovers Near SupportTurnaround Stocks - po-news-eg.net
Thomas (tc) Chan Net Worth (2026) - GuruFocus
GoodRx Holdings Inc (FRA:8GH) Stock Price, Trades & News - GuruFocus
Form 4 Goodrx Holdings Inc For: 16 July By Investing.com - Investing.com Nigeria
GoodRx Holdings (GDRX) officer exercises RSUs, withholds shares for taxes - Stock Titan
GoodRx Holdings (NASDAQ: GDRX) insider converts RSUs, covers tax with stock - Stock Titan
GoodRx (GDRX) CAO exercises RSUs and withholds shares for taxes - Stock Titan
Frontier tech research, news & data - MLQ.ai
GoodRx (GDRX) Q4 2025 earnings summary - Quartr
GDRX Q1 2026 Earnings: EPS Misses Estimates, Stock Gains on ResilienceProfitability Analysis - dars.gov.et
GDRX or HQY: Which is the better value stock right now? - MSN
GoodRx (GDRX) Stock Trades Up, Here Is Why - Yahoo Finance
GoodRx Holdings (GDRX) Pharma Growth Story Meets A Small Fair Value Gap - Yahoo Finance
GoodRx (GDRX) Stock Looks Full On Earnings But Mixed On Value - Yahoo Finance
GoodRx (GDRX) Q1 2025 earnings summary - Quartr
GoodRx sets date for Q2FY26 earnings release - scanx.trade
Press Release: GoodRx Announces Date for Second Quarter 2026 Earnings Release and Conference Call - Moomoo
GoodRx sets Aug. 5 earnings release, Aug. 6 call - Stock Titan
GoodRx Announces Date for Second Quarter 2026 Earnings Release and Conference Call - Business Wire
GoodRx (GDRX) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
GDRX or HQY: Which Is the Better Value Stock Right Now? - Yahoo Finance
Is GoodRx (GDRX) Stock Undervalued Right Now? - Yahoo Finance
Earnings call transcript: GoodRx Q1 2026 revenue exceeds forecasts - Investing.com
GDRXGoodRx Holdings Inc Options - Finviz
GDRX.O - Reuters
3 Penny Stocks Under $8B Market Cap Worth Watching - simplywall.st
Enterprise value to revenue forward of GoodRx Holdings, Inc. – NASDAQ:GDRX - TradingView
GoodRx Holdings Inc (GDRX) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
Enterprise value to revenue forward of GoodRx Holdings, Inc. – BOATS:GDRX - TradingView
Price to sales forward of GoodRx Holdings, Inc. – NASDAQ:GDRX - TradingView
Price to sales forward of GoodRx Holdings, Inc. – BOATS:GDRX - TradingView
GoodRx Holdings, Inc. Class A Actuals & Estimates (NASDAQ:GDRX) - TradingView
Enterprise value to EBITDA forward of GoodRx Holdings, Inc. – BOATS:GDRX - TradingView
GDRX Forecast — Price Target — Prediction for 2027 - TradingView
Price to book forward of GoodRx Holdings, Inc. – BOATS:GDRX - TradingView
Enterprise value to EBIT forward of GoodRx Holdings, Inc. – NASDAQ:GDRX - TradingView
Price to earnings forward of GoodRx Holdings, Inc. – NASDAQ:GDRX - TradingView
Goodrx Holdings Inc Azioni (GDRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Goodrx Holdings Inc Azioni (GDRX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| REY-GIRAUD AGNES | Director |
Mar 12 '26 |
Option Exercise |
0.47 |
192,185 |
90,327 |
277,633 |
| Spectrum Equity VII, L.P. | 10% Owner |
Oct 15 '25 |
Sale |
4.00 |
23,771 |
95,103 |
0 |
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):